About this book:

DaVita began in 1979 as Medical Ambulatory Care, Inc., founded to provide outpatient dialysis after Medicare’s commitment to fund the treatment created a stable revenue stream. After years of fragmented growth through acquisitions, the company—renamed Total Renal Care—collapsed under $1.2 billion of debt and a plunging stock price in the late‑1990s. In October 1999 Kent J. Thiry arrived as CEO and initiated a dramatic turnaround: he restructured debt, rebranded the company as DaVita (meaning “to give life”), and instituted a values‑based culture called “The DaVita Way,” emphasizing Service Excellence, Integrity, Team, Continuous Improvement, Accountability, Fulfillment, and Fun. This cultural overhaul, supported by DaVita University, the DaVita Village Network, and early investments in clinical software, rebuilt trust, reduced turnover, and laid the foundation for sustainable growth.

With stability restored, DaVita pursued disciplined expansion, most notably the 2005 acquisition of Gambro Healthcare, which doubled its size and cemented its place as one of the two dominant U.S. dialysis providers alongside Fresenius Medical Care. The company extended its reach through organic clinic openings, strategic physician partnership models that gave nephrologists equity stakes, and international ventures in Germany, China, Latin America, and elsewhere, adapting its “Village” ethos to local contexts. Simultaneously, DaVita invested heavily in dialysis technology—upgrading machines, water‑purification systems, electronic health records, and telemedicine platforms—while navigating a heavily regulated reimbursement landscape dominated by Medicare and overcoming significant legal settlements related to billing practices.

As healthcare reform shifted toward value‑based care, DaVita embraced models such as ESRD Seamless Care Organizations (ESCOs) and the Kidney Care Choices (KCC) program, focusing on coordinated chronic kidney‑care management, home dialysis promotion, and integrated services like pharmacy, vascular access, and behavioral health. Leadership transitioned in 2019 from Thiry to longtime executive Javier J. Rodriguez, who preserved the core culture while accelerating digital transformation, AI‑driven predictive analytics, and a joint venture with Medtronic to develop next‑generation home‑dialysis equipment. Throughout its evolution, DaVita maintained a strong commitment to teammate development, community engagement, and social impact, leveraging its scale and culture to drive superior clinical outcomes—including the industry’s lowest mortality rate—and to expand beyond dialysis into comprehensive kidney‑care and population‑health initiatives. The company’s legacy lies in its demonstration that a purpose‑driven, values‑centered organization can achieve both financial success as an S&P 500 member and a profound, lasting impact on patient well‑being and the broader healthcare ecosystem.

What You'll Find Inside:

• The remarkable turnaround of DaVita from near-bankruptcy in 1999 to an S&P 500 healthcare leader, driven by Kent Thiry's cultural transformation and operational discipline.
• How 'The DaVita Way'—a unique 'Village' culture built on core values like Service Excellence, Integrity, Team, and Fun—became a sustainable competitive advantage and driver of employee engagement.
• Strategic growth through disciplined acquisitions (notably Gambro Healthcare), the innovative Physician Partnership Model, and expansion into integrated kidney care and value-based payment models.
• Navigating complex regulatory landscapes and healthcare reform, including the shift from fee-for-service to value-based care via ESCOs and the KCC Model, while managing compliance and reimbursement challenges.
• The evolving role of technology—from early EHR adoption to AI-driven predictive analytics, home dialysis platforms, and the Medtronic joint venture—in shaping the future of kidney care delivery.

Who's It For:

This book is ideal for healthcare executives, business leaders, and investors seeking a detailed case study of a successful corporate turnaround and culture-driven growth strategy. It will also benefit healthcare policy analysts, nephrology professionals, and students of organizational behavior who want to understand the intersection of clinical operations, regulatory navigation, and value-based care innovation in the dialysis industry.